World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
113
Citations
47160
World Ranking
4956
National Ranking
488

Christopher R. Chapple publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Christopher R. Chapple sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 1,217 publications — 97th percentile

97% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Christopher R. Chapple D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Christopher R. Chapple sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 113 D-Index — 76th percentile

76% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Christopher R. Chapple is a researcher affiliated with the Royal Hallamshire Hospital in the United Kingdom. Their work spans extensively within the field of Medicine, focusing primarily on Urology and its related subfields. The subfields of study associated with their research include Rheumatology, Surgery, Epidemiology, and Pulmonary and Respiratory Medicine.

The scientist's research delves into various topics largely concerning urinary health and urological disorders. Notable topics covered include:

  • Urinary Bladder and Prostate Research
  • Pelvic floor disorders treatments
  • Urological Disorders and Treatments
  • Urinary Tract Infections Management
  • Urologic and reproductive health conditions
  • Urinary and Genital Oncology Studies
  • Prostate Cancer Diagnosis and Treatment

Christopher R. Chapple has contributed to multiple scholarly articles across leading publication venues, with frequent appearances in:

  • Neurourology and Urodynamics
  • European Urology
  • European Urology Focus
  • The Journal of Urology
  • Faculty Opinions - Post-Publication Peer Review of the Biomedical Literature

Several recent papers illustrate the scope and collaboration in their work, including:

  • European Association of Urology Guidelines Office Rapid Reaction Group: An Organisation-wide Collaborative Effort to Adapt the European Association of Urology Guidelines Recommendations to the Coronavirus Disease 2019 Era (2020), published in European Urology
  • Prostate-specific Antigen Testing as Part of a Risk-Adapted Early Detection Strategy for Prostate Cancer: European Association of Urology Position and Recommendations for 2021 (2021), published in European Urology
  • Diagnostic Assessment of Lower Urinary Tract Symptoms in Men Considering Prostate Surgery: A Noninferiority Randomised Controlled Trial of Urodynamics in 26 Hospitals (2020), published in European Urology
  • A Systematic Review of Surgical interventions for the Treatment of Bladder Pain Syndrome/Interstitial Cystitis (2020), published in European Urology Focus
  • Efficacy and Safety of Mirabegron versus Placebo Add-On Therapy in Men with Overactive Bladder Symptoms Receiving Tamsulosin for Underlying Benign Prostatic Hyperplasia: A Randomized, Phase 4 Study (PLUS) (2020), published in The Journal of Urology

Their research collaborations include frequent co-authors such as Nadir I. Osman, Paul Abrams, Naşide Mangır, Marcus J. Drake, and Richard Inman, reflecting sustained partnerships in clinical and academic investigations.

Best Publications

  • The Effects of Antimuscarinic Treatments in Overactive Bladder: An Update of a Systematic Review and Meta-Analysis

    Christopher R. Chapple;Vik Khullar;Zahava Gabriel;Dominic Muston

  • The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: results from the Epidemiology of LUTS (EpiLUTS) study.

    Karin S. Coyne;Chris C. Sexton;Christine L. Thompson;Ian Milsom

  • Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder

    Paul Abrams;Karl Erik Andersson;Jerry J. Buccafusco;Christopher Chapple

  • EAU guidelines on urinary incontinence

    J. W. Thüroff;P. Abrams;K. E. Andersson;Walter Artibani

  • A Shifted Paradigm for the Further Understanding, Evaluation, and Treatment of Lower Urinary Tract Symptoms in Men: Focus on the Bladder

    Christopher R. Chapple;Claus G. Roehrborn

  • Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial.

    Roger Dmochowski;Christopher Chapple;Victor W. Nitti;Michael Chancellor

  • OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial

    Christopher Chapple;Karl-Dietrich Sievert;Scott MacDiarmid;Vik Khullar

  • Randomized Double-blind, Active-controlled Phase 3 Study to Assess 12-Month Safety and Efficacy of Mirabegron, a β3-Adrenoceptor Agonist, in Overactive Bladder

    Christopher R. Chapple;Steven A. Kaplan;David Mitcheson;Jiri Klecka

  • A Comparison of the Efficacy and Tolerability of Solifenacin Succinate and Extended Release Tolterodine at Treating Overactive Bladder Syndrome: Results of the STAR Trial

    C.R. Chapple;R. Martinez-Garcia;L. Selvaggi;P. Toozs-Hobson

  • Updated Systematic Review and Meta-analysis of the Comparative Data on Colposuspensions, Pubovaginal Slings, and Midurethral Tapes in the Surgical Treatment of Female Stress Urinary Incontinence

    Giacomo Novara;Walter Artibani;Matthew D. Barber;Christopher R. Chapple

  • MUSCARINIC RECEPTOR ANTAGONISTS IN THE TREATMENT OF OVERACTIVE BLADDER

    Christopher R. Chapple

  • Detrusor Underactivity and the Underactive Bladder: A New Clinical Entity? A Review of Current Terminology, Definitions, Epidemiology, Aetiology, and Diagnosis

    Nadir I. Osman;Christopher R. Chapple;Paul Abrams;Roger Dmochowski

  • Urinary Incontinence and its Relationship to Mental Health and Health-Related Quality of Life in Men and Women in Sweden, the United Kingdom, and the United States

    Karin S. Coyne;Marion Kvasz;Andrea M. Ireland;Ian Milsom

  • Evaluation and Treatment of Lower Urinary Tract Symptoms in Older Men

    P. Abrams;C. Chapple;S. Khoury;Claus Roehrborn

  • The ICS–‘BPH’ Study: the psychometric validity and reliability of the ICSmale questionnaire

    J.L. Donovan;P. Abrams;T.J. Peters;H.E. Kay

  • Silodosin Therapy for Lower Urinary Tract Symptoms in Men with Suspected Benign Prostatic Hyperplasia: Results of an International, Randomized, Double-Blind, Placebo- and Active-Controlled Clinical Trial Performed in Europe

    Christopher R. Chapple;Francesco Montorsi;Teuvo L.J. Tammela;Manfred Wirth

  • The Effects of Antimuscarinic Treatments in Overactive Bladder: A Systematic Review and Meta-Analysis

    Christopher Chapple;Vik Khullar;Zahava Gabriel;Julie Ann Dooley

  • Clinical Efficacy, Safety, and Tolerability of Once-Daily Fesoterodine in Subjects with Overactive Bladder

    Christopher Chapple;Philip Van Kerrebroeck;Andrea Tubaro;Cornelia Haag-Molkenteller

  • Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. A meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group.

    C. R. Chapple;J. J. Wyndaele;J. Nordling;F. Boeminghaus

  • Urothelium-derived inhibitory factor(s) influences on detrusor muscle contractility in vitro.

    M H Hawthorn;C R Chapple;M Cock;R Chess-Williams

Frequent Co-Authors

Sheila MacNeil
Sheila MacNeil University of Sheffield
Paul Abrams
Paul Abrams Southmead Hospital
Ian Milsom
Ian Milsom University of Gothenburg
Luke Vale
Luke Vale Newcastle University
Linda Cardozo
Linda Cardozo University of Cambridge
Alan J. Wein
Alan J. Wein University of Miami
Dirk De Ridder
Dirk De Ridder University of Otago
Karl-Erik Andersson
Karl-Erik Andersson Lund University
Roger R. Dmochowski
Roger R. Dmochowski Vanderbilt University Medical Center
Claus G. Roehrborn
Claus G. Roehrborn The University of Texas Southwestern Medical Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine doesn’t always mean attending traditional, on-campus programs. Today, there are diverse online pathways that prepare you for specialized roles in the healthcare sector. For registered nurses looking to advance, adn to np bridge programs offer an efficient route to becoming a nurse practitioner, often without leaving your job.

If you’re interested in holistic health, pursuing a nutrition bachelor degree online can open doors to careers in dietetics, wellness coaching, or food policy. For those inclined toward leadership, cahme accredited online healthcare administration programs are essential for acquiring skills in healthcare policy, operations, and management—crucial for high-level administrative roles.

Additionally, busy registered nurses can consider rn to bsn without clinicals programs, which provide academic advancement in a flexible format. Each of these online degree options supports career growth while balancing life’s other commitments.

Best Scientists Citing Christopher R. Chapple

Trending Scientists

Recently Published Articles